Liontrust Investment Partners’s iRadimed IRMD Stock Holding History

Liontrust Investment Partners’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.03M	Hold	21,255	–	–	0.03%	148
2026 Q1	$2.05M	Sell	21,255 -15,216	-42%	-$1.52M	0.03%	147
2025 Q4	$3.55M	Sell	36,471 -1,315	-3%	-$113K	0.05%	147
2025 Q3	$2.69M	Sell	37,786 -1,168	-3%	-$77.8K	0.04%	142
2025 Q2	$2.33M	Sell	38,954 -1,467	-4%	-$80.4K	0.03%	151
2025 Q1	$2.12M	Sell	40,421 -28,783	-42%	-$1.62M	0.03%	147
2024 Q4	$3.81M	Buy	69,204 +4,808	+7%	+$253K	0.06%	128
2024 Q3	$2.83M	Hold	64,396	–	–	0.04%	137
2024 Q2	$2.83M	Buy	+64,396	New	+$2.74M	0.04%	137

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Liontrust Investment Partners's IRMD Position: Q2 2026 in Review

Liontrust Investment Partners held its iRadimed (IRMD) position steady in Q2 2026 at 21,255 shares worth $2.03M. The position accounts for 0.03% of the portfolio, ranked #148.

Liontrust Investment Partners first reported a position in IRMD in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.81M in Q4 2024. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Liontrust Investment Partners held 21,255 shares of iRadimed worth $2.03M as of Q2 2026.
Liontrust Investment Partners left its iRadimed share count unchanged in Q2 2026.
iRadimed made up 0.03% of Liontrust Investment Partners's portfolio in Q2 2026, its #148 holding.
Liontrust Investment Partners first reported a position in iRadimed in Q2 2024 and has held it in 9 quarters since.
Liontrust Investment Partners's iRadimed position peaked at $3.81M in Q4 2024.
214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Liontrust Investment Partners's 13F filing for Q2 2026, filed 18 Aug 2026.